ストックスクリーナーアプリを入手
4.61
5.01%
0.22
前日終値:
$4.39
開ける：
$4.43
24時間の取引高:
496.45K
Relative Volume:
0.86
時価総額：
$255.78M
収益：
$192.64M
当期純損益:
$2.51M
株価収益率:
87.98
EPS:
0.0524
ネットキャッシュフロー:
$12.42M
1週間 パフォーマンス:
+6.22%
1か月 パフォーマンス:
+5.49%
6か月 パフォーマンス:
-4.75%
1年 パフォーマンス:
-26.48%
1日の値動き範囲:
$4.405
$4.62
1週間の範囲:
$4.24
$4.62
52週間の値動き範囲:
$3.8092
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
名前
Vanda Pharmaceuticals Inc
セクター
電話
202-734-3400
住所
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.61 | 255.78M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-31 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-25 | ダウングレード | Jefferies | Buy → Hold |
| 2021-05-12 | 開始されました | BofA Securities | Buy |
| 2021-01-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-03-16 | ダウングレード | Oppenheimer | Perform → Underperform |
| 2020-03-12 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-08-01 | アップグレード | Citigroup | Neutral → Buy |
| 2019-07-25 | ダウングレード | Stifel | Buy → Hold |
| 2018-12-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2018-12-04 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 繰り返されました | Jefferies | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-09-21 | 再開されました | Oppenheimer | Outperform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2017-09-14 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-06-27 | 再開されました | Piper Jaffray | Overweight |
| 2017-05-26 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-12 | 開始されました | Oppenheimer | Outperform |
| 2016-11-09 | 開始されました | Aegis Capital | Buy |
| 2016-10-06 | 再開されました | Jefferies | Buy |
すべてを表示
Vanda Pharmaceuticals Inc (VNDA) 最新ニュース
Vanda Approves Key Proposals at Annual Meeting - TipRanks
SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow
CLASS ACTION UPDATE for SPB, VNDA and ARA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Class Action Reminder Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire
Judge Favors Vanda But Seeks Deal Over Drug Approval - Law360
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting - PR Newswire
SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow
Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan
Justices Urged To Undo Denial Of Fast Track For Gastro Drug - Law360
Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis - MarketBeat
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus
President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow
Insider Buying: Mihael Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus
President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4) - Quantisnow
Mystics enter new partnership with Vanda Pharmaceuticals - Monumental Sports Network
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - The Malaysian Reserve
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 | VNDA Stock News - GuruFocus
Mystics tap D.C.'s Vanda Pharmaceuticals as new jersey sponsor - The Business Journals
Monumental Sports & Entertainment Announces Vanda Pharmaceuticals Inc. as Official Partner and Jersey Patch Partner for the Washington Mystics - Monumental Sports
Vanda Pharmaceuticals (VNDA) Receives Overweight Rating from Can - GuruFocus
Vanda Pharmaceuticals (VNDA) Projected to Transform with Overwei - GuruFocus
Vanda Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald - TipRanks
Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union | Libero Quotidiano.it - Libero Quotidiano
Vanda Pharmaceuticals’ (VNDA) “Buy” Rating Reiterated at HC Wainwright - Defense World
Vanda pharmaceuticals outlines $210M-$250M revenue target for 2025 amid product launches - MSN
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates - MSN
Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges - TipRanks
Vanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance
Vanda: Q1 Earnings Snapshot - MySA
Vanda Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Vanda Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.50 Beats - GuruFocus
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2025 forecasts - Investing.com
Capitals Announce Game 3 Watch Party at The Wharf as Part of Additional Playoffs Initiatives Presented by Vanda Pharmaceuticals Inc. - NHL.com
Vanda Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.50 Beats Estimate, Revenue Surpasses Forecast at $50 Million - GuruFocus
Vanda Pharmaceuticals (VNDA) Reports Strong Q1 Revenue and Expands Product Pipeline | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results - StreetInsider
HC Wainwright & Co. Reiterates Buy Rating on Vanda Pharmaceutica - GuruFocus
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial R - GuruFocus
A Glimpse of Vanda Pharma's Earnings Potential - Nasdaq
3 Penny Stocks Under $300M Market Cap To Consider - simplywall.st
Vanda Pharmaceuticals Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
Drugmaker Vanda Announces Bysanti NDA Filing - marketscreener.com
FDA Begins Review Process on Vanda Pharmaceuticals' (VNDA) Drug - GuruFocus
FDA accepts Vanda’s new antipsychotic drug for review By Investing.com - Investing.com India
FDA accepts Vanda’s new antipsychotic drug for review - Investing.com
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Inc (VNDA) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):